Medications

Pharmaceutical advertising down but not out, study says

The pharmaceutical industry has pulled back on marketing to physicians and consumers, yet some enduring patterns persist. According to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health, ...

Diseases, Conditions, Syndromes

Rivaroxaban found noninferior to enoxaparin in acutely ill

(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, ...

Medications

The drugs don't work

(Medical Xpress)—Drugs that do not represent value for money or are medically unproven may be increasingly reaching one of Europe's largest pharmaceutical markets, according to research undertaken by Cambridge sociologist ...

Other

COI declarations and off-label drug use

Conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, ...

Medications

Indian expert panel to probe drugs regulator

India's Health Ministry said Friday it had set up an expert panel to review the operations of its drug regulatory agency, accused of colluding with pharmaceutical firms to approve drugs without trials.

Medications

India probes charges of violations by drugs regulator

India's Health Ministry said Thursday it was examining charges that the government's top drug regulatory agency had colluded with pharmaceutical firms to approve drugs without proper clinical trials.

page 4 from 5